JD BIO Successfully Concludes Participation as Main Sponsor at 'AMWC KOREA 2026'
Global beauty and medical aesthetics company JD BIO Co., Ltd. successfully participated as the Main Sponsor at AMWC KOREA 2026, one of the world's leading congresses in aesthetic and anti-aging medicine, held at the InterContinental Grand Seoul Parnas.
During the two-day event, held from June 19 to 20, JD BIO showcased its flagship medical aesthetics portfolio at its large-scale exhibition booth, attracting physicians, industry professionals, and international buyers from around the world.
Featured products included the highly purified botulinum toxins OneTox and Red Tox, the RICHESSE™ Red Volume No.7 and No.9 fillers developed with patented HLD technology for precise volumization, and the DEMEI™ Body 60 and Body 100 body fillers, recognized for their excellent tissue integration. The products generated strong interest from physicians and international buyers throughout the exhibition.
In particular, during the JD Bio-sponsored Lunch Symposium on the second day of the congress, the CEO of JD Bio delivered a keynote presentation titled "The Future of Medical Aesthetics and Innovation in Biotechnology." The session showcased JD Bio's unique R&D philosophy and long-term vision for next-generation aesthetic solutions, reinforcing the confidence of global distribution partners and drawing significant attention from attendees.
The symposium also featured a renowned aesthetic medicine specialist, who introduced CHP, JD Bio's innovative next-generation biomaterial. In a presentation titled "Beyond Hydration: Overcoming the Limitations of Conventional Skin Boosters with CHP," the speaker shared compelling clinical data demonstrating how JD Bio's CHP technology enhances post-procedure skin recovery, promotes skin stabilization, and supports regeneration. The presentation generated strong interest among physicians, distributors, and other industry professionals.
In addition, DR. RICHESSE, the premium high-functional skincare brand developed by JD BIO's subsidiary JD Skin Lab, introduced its P.E.C 360 Revine line. Featuring JD BIO's proprietary blend of PDRN, exosomes, and collagen, the products' technology was highly recognized and led to successful meetings with numerous international distributors.
"Participating as the Main Sponsor of AMWC KOREA 2026 provided an excellent opportunity to showcase JD BIO's technological expertise while strengthening our global brand presence," said a JD BIO representative. "We will continue to drive innovation through ongoing R&D and expand our global network to lead the future of the medical aesthetics industry."